Endometriosis Fertility and Outcomes

Risk of endometriosis progression in infertile women trying to conceive naturally or using IVF

Somigliana E, Vigano P, Invernici D, Fornelli G, Merli CEM, Vercellini P

Published July 2025 Human Reproduction
DOI 10.1093/humrep/deaf090 PMID 40344687 PMC PMC12222615

RRM Academy Synopsis

Endometriosis recurs about 10% a year without hormonal therapy

Among women with endometriosis who stop medical therapy to conceive, a 2025 expert review puts yearly recurrence at about 10%. It also covers IVF and deep disease, where two studies differed.

About 1 in 10 women with endometriosis who stop medical therapy to conceive have a recurrence each year
About 1 in 10 women with endometriosis who stop medical therapy to conceive have a recurrence each year. Source: Somigliana E et al., 2025, PMID 40344687.
Study at a glance, narrative review: Endometriosis recurs about 10% a year after stopping medical therapy
Study at a glance, narrative review: Endometriosis recurs about 10% a year after stopping medical therapy. Source: Somigliana E et al., 2025, PMID 40344687.

Key Findings

  • The authors support a yearly recurrence risk of ∼10% for women off medical therapy, which they also give as about 10% over the typical 1-year timeframe.
  • Bandini et al. (2024) pooled four studies of untreated deep endometriosis to 21% progression (95% CI: 7–41%) over 22 to 65 months. Medical therapy users had 12% recurrence (95% CI: 9–16%).
  • Knez et al. (2024) followed 120 endometriomas in 83 women for a median of 21 months. Twenty-eight lesions grew (23%, 95% CI: 16–32%).
  • Seyer-Hansen et al. followed 77 women with unoperated bowel deep endometriosis having IVF. Ten (13%, 95% CI: 7–22%) had severe symptom worsening, and all 10 needed surgery.
  • Berlanda et al. (2019) reviewed 60 women with deep endometriosis who had failed IVF. One woman (2%, 95% CI: 0.1–8%) had a significant complication, a transient ureteral stenosis.

Interpretation

The paper is a narrative review by experts, paired with an updated review of deep endometriosis progression. The recurrence figure comes from earlier studies. The two IVF groups examined different disease sites and got different results. Bowel disease had a higher rate of symptoms getting worse than deep disease overall. The authors say their advice on IVF cycles is speculative. The findings support larger studies of endometriosis recurrence after women stop medical therapy.

RRM Context

The review states that hormonal therapies protect only while women use them. Suppressive medications manage endometriosis and leave the disease in place. Restorative reproductive medicine looks for the underlying disease in both partners and treats it, with excision as the surgical standard. IVF bypasses infertility and does not treat endometriosis.

Abstract

The use of hormonal treatments for endometriosis has increased in recent years. Their effectiveness lies in creating a stable hormonal environment, reducing peripheral estrogen levels, and suppressing ovulation and menstruation. Although these agents do not cure endometriosis and symptoms often return after discontinuation, they effectively relieve pain in most cases and help prevent disease progression or recurrence. Women are therefore typically managed with long-term hormonal treatments, with or without surgery. However, this approach is unsuitable for those seeking natural pregnancy or undergoing IVF, as all hormonal treatments hinder conception. For women pursuing natural pregnancy, these treatments should be discontinued for about 1 year, the time needed to diagnose infertility. However, this suspension exposes women to the risk of recurrence or progression and is therefore clinically acceptable only if the woman has a reasonable likelihood of achieving pregnancy naturally. In women with endometriosis who are infertile and therefore require IVF, ovarian stimulation significantly raises estrogen levels-up to 10 times those of a natural cycle-potentially boosting the risk of endometriosis relapse. Evidence is reassuring on this issue even if some limited data suggest that ovarian stimulation may promote deep invasive endometriosis progression. Overall, physicians and patients must balance the chances of natural or ART-assisted pregnancy against the risk of disease recurrence or progression during treatment discontinuation or IVF. This choice is also complicated by the increased risk of severe pregnancy complications in women with endometriosis, possibly depending on the conception method. This review discusses the available evidence that can be helpful in guiding the decision-making process.

Read the guide

Topics

By this author

Related research

Endometriosis › Fertility and Outcomes › Conception After Excision · Therapeutics › Hormonal Agents › Gonadotropins · Reproductive Endocrinology › Ovarian Hormones › Estrogen
Edgardo Somigliana, Paola Vigano, Dalila Invernici, Gianfranco Fornelli, Camilla Erminia Maria Merli, Paolo Vercellini
E Somigliana, P Vigano, D Invernici, G Fornelli, C Merli, P Vercellini
PMID 40344687 40344687 DOI 10.1093/humrep/deaf090 10.1093/humrep/deaf090 Somigliana et al. 2025, Somigliana 2025